Basilea - Still capturing value from oncology

Basilea - Focus on anti-infectives apparent

Basilea - Dilution overhang removed

Basilea - H1 results show continued commercial and strategic progress

Diurnal Group - Trading update ahead of R&D Day

Basilea - Positive Phase 3 results

Basilea - New positioning apparent

Basilea - New territory growth

Basilea - The prospects for anti-infectives

Basilea - Boosting the anti-fungal franchise

Diurnal Group - Efmody set for Swiss launch with EffRx

Diurnal Group - European commercial roll-out continues

Diurnal Group - SMC decision, financial results and outlook

Diurnal Group - Commercial rollout continues

Basilea - Refocusing on anti-infectives

Diurnal Group - SMC decision another hurdle to jump

Basilea - Strategic repositioning

Diurnal Group - The AI and TRT opportunities

Diurnal Group - Efmody moving into larger AI disorder

Diurnal Group - Trading update ahead of R&D day